Tamoxifen citrate tablets

A technology of tamoxifen and citric acid, applied in the directions of organic active ingredients, non-active ingredients of polymer compounds, pharmaceutical formulations, etc., can solve problems such as low bioavailability

Active Publication Date: 2015-04-01
NANTONG GUANGTAI BIOCHEM PROD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the shortcoming of low bioavailability of existing tamoxifen citrate preparations, the present invention has invented tamoxifen citrate inclusion compound tablet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tamoxifen citrate tablets
  • Tamoxifen citrate tablets
  • Tamoxifen citrate tablets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Prescription

[0034] Tamoxifen citrate inclusion compound: Tamoxifen citrate: α-cyclodextrin ratio is 1:2

[0035] Tamoxifen citrate inclusion compound 20.5 parts

[0036] Composition of starch and microcrystalline cellulose (the weight ratio of the two is 5.1:2.9) 18.5 parts

[0037] 11 parts of 3% polyvinylpyrrolidone 95% ethanol solution

[0038] Sodium alginate 8 parts

[0039] Composition of croscarmellose sodium and sodium carboxymethyl starch

[0040] (The weight ratio of the two is 3.3:4.7) 27 parts

[0041] Micropowder silica gel 4.6 parts

[0042] Preparation:

[0043] 1. Prepare tamoxifen citrate inclusion compound according to the following method:

[0044] (1) In water or aqueous ethanol medium, react tamoxifen citrate with α-cyclodextrin in a certain proportion, filter the resulting solution through a microporous membrane until clarified, and separate the inclusion complex from the mixture thing; or

[0045] (2) In solid form, reacting ...

Embodiment 2

[0049] Fully grind tamoxifen citrate and α-cyclodextrin described in Example 1 in 50% ethanol to form a uniform paste, and obtain a white powder after vacuum drying. Tamoxifen citrate increased 12-fold.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to tamoxifen citrate tablets which are prepared by the following steps: firstly, preparing tamoxifen citrate to inclusion compounds; and then, preparing the tablets.

Description

technical field [0001] The present application relates to a tablet, specifically, a tamoxifen citrate inclusion complex tablet. Background technique [0002] Tamoxifen (TAM) is a non-steroidal compound approved by the US Food and Drug Administration in 1977 for the treatment of metastatic breast cancer in postmenopausal women. After nearly 30 years of application history, it is now also used to prevent the occurrence of breast cancer. TAM belongs to the first generation of selective estrogen receptor modulators (selective estrogen receptor modulators, SERMs), which have dual effects of estrogen agonism and estrogen antagonism, and this effect depends on different germlines, tissues and gene expression types, Different target organs or target cells have different effects. For example, TAM produces antagonizing estrogen in mammary gland tissue, while it produces estrogen agonizing effect in uterus and bone tissue. TAM competes with estrogen for the estrogen receptor (ER) in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/36A61K31/138A61K47/40A61P35/00
Inventor 李申李春涛邱俊
Owner NANTONG GUANGTAI BIOCHEM PROD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products